Eric Lawitz1, Robert Flisiak2, Manal Abunimeh3, Meghan E Sise4, Jun Y Park5, Marwan Kaskas6, Annette Bruchfeld7, Marcus-Alexander Wörns8, Andrea Aglitti9, Philippe J Zamor10, Zhenyi Xue3, Gretja Schnell3, Yash J Jalundhwala3, Ariel Porcalla3, Federico J Mensa3, Marcello Persico9. 1. The Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX, USA. 2. Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland. 3. AbbVie, Inc., North Chicago, IL, USA. 4. Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA. 5. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. 6. Northwest Louisiana Nephrology, Shreveport, LA, USA. 7. Department of Renal Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. 8. Department of Internal Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. 9. Internal Medicine and Hepatology Unit, University of Salerno, Salerno, Italy. 10. Carolinas Medical Center, Charlotte, NC, USA.
Abstract
BACKGROUND AND AIMS: Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Previously available direct-acting antiviral regimens are not approved for patients with advanced CKD across all HCV genotypes. METHODS: EXPEDITION-5 is a phase 3 study to evaluate efficacy and safety of the fixed-dose combination of glecaprevir and pibrentasvir (G/P) for chronic HCV infection (genotype 1 through 6) in adults without cirrhosis or with compensated cirrhosis and with stage 3b, 4 or 5 CKD. Patients received approved duration of G/P according to HCV genotype, cirrhosis status and prior HCV treatment experience. The primary efficacy endpoint was percentage of patients with sustained virologic response at 12 weeks post-treatment (SVR12). RESULTS: Among the 101 patients enrolled in the study, 24% had predialysis CKD and 76% were on dialysis. Eighty-four patients were treated with G/P for 8 weeks, 13 patients for 12 weeks and four patients for 16 weeks. Fifty-five per cent of patients had genotype 1, 27% had genotype 2, 15% had genotype 3 and 4% had genotype 4, and none had genotype 5 or 6 infection. The SVR12 rate was 97% (98/101, 95% confidence interval, 91.6-99.0). No patients experienced virologic failure. Adverse events (AEs) reported in at least 5% of the patients were pruritus, bronchitis, hypertension and generalized pruritus. Serious AEs were reported in 12% of patients; none related to study drug. CONCLUSIONS: G/P treatment yielded high SVR12 rates irrespective of the presence of stage 3b, 4 or 5 CKD. No safety signals were detected. CLINICALTRIALS. GOV IDENTIFIER: This Phase 3 clinical trial was funded by AbbVie and registered with clinicaltrials.gov as NCT03069365 (EXPEDITION-5).
BACKGROUND AND AIMS: Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Previously available direct-acting antiviral regimens are not approved for patients with advanced CKD across all HCV genotypes. METHODS: EXPEDITION-5 is a phase 3 study to evaluate efficacy and safety of the fixed-dose combination of glecaprevir and pibrentasvir (G/P) for chronic HCV infection (genotype 1 through 6) in adults without cirrhosis or with compensated cirrhosis and with stage 3b, 4 or 5 CKD. Patients received approved duration of G/P according to HCV genotype, cirrhosis status and prior HCV treatment experience. The primary efficacy endpoint was percentage of patients with sustained virologic response at 12 weeks post-treatment (SVR12). RESULTS: Among the 101 patients enrolled in the study, 24% had predialysis CKD and 76% were on dialysis. Eighty-four patients were treated with G/P for 8 weeks, 13 patients for 12 weeks and four patients for 16 weeks. Fifty-five per cent of patients had genotype 1, 27% had genotype 2, 15% had genotype 3 and 4% had genotype 4, and none had genotype 5 or 6 infection. The SVR12 rate was 97% (98/101, 95% confidence interval, 91.6-99.0). No patients experienced virologic failure. Adverse events (AEs) reported in at least 5% of the patients were pruritus, bronchitis, hypertension and generalized pruritus. Serious AEs were reported in 12% of patients; none related to study drug. CONCLUSIONS: G/P treatment yielded high SVR12 rates irrespective of the presence of stage 3b, 4 or 5 CKD. No safety signals were detected. CLINICALTRIALS. GOV IDENTIFIER: This Phase 3 clinical trial was funded by AbbVie and registered with clinicaltrials.gov as NCT03069365 (EXPEDITION-5).
Authors: Farina M Hanif; Zain Majid; Nasir Hassan Luck; Abbas Ali Tasneem; Syed Muddasir Laeeq; Muhammed Mubarak Journal: World J Hepatol Date: 2022-04-27
Authors: Olga Tronina; Magdalena Durlik; Iwona Orłowska; Beata Lorenc; Tadeusz W Łapiński; Aleksander Garlicki; Dorota Dybowska; Dorota Zarębska-Michaluk; Magdalena Tudrujek-Zdunek; Jolanta Citko; Ewa Janczewska; Marcin Kaczmarczyk; Jerzy Jaroszewicz; Rafał Krygier; Jakub Klapaczyński; Beata Dobracka; Jolanta Białkowska-Warzecha; Anna Piekarska; Krzysztof Simon; Waldemar Halota; Małgorzata Pawłowska; Krzysztof Tomasiewicz; Robert Flisiak Journal: Ann Gastroenterol Date: 2021-02-05
Authors: Robert S Brown; Michelle A Collins; Simone I Strasser; Amanda Emmett; Andrew S Topp; Margaret Burroughs; Rosa Ferreira; Jordan J Feld Journal: Infect Dis Ther Date: 2022-02-17
Authors: Paweł Pabjan; Michał Brzdęk; Magdalena Chrapek; Kacper Dziedzic; Krystyna Dobrowolska; Katarzyna Paluch; Anna Garbat; Piotr Błoniarczyk; Katarzyna Reczko; Piotr Stępień; Dorota Zarębska-Michaluk Journal: Viruses Date: 2022-01-06 Impact factor: 5.048